The Relationship Between ADT and Cardiovascular Evens In German Men

ASCO GU has given us a number of interesting posters, some of which I have already written about in prior posts. Another of these posters (abstract 232)  was about an analysis by Ruessel and colleagues describing cardiovascular events among men with prostate cancer using German claims data. The researchers, in a retrospective study, attempted to both evaluate the relationship between androgen deprivation therapy (ADT) and cardiovascular events and to determine if the cardiovascular risk was different for men who were treated with GnRH antagonists vs. agonists. They used a German research database from the Health Risk Institute. They compared men [...]

German Registry Data Analysis of Degarelix (Firmagon®) for Prostate Cance

The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common it is important to understand both its safety and efficacy as compared to our older standard drugs. The best way to track this type of information is through a registry. This was done when researchers, using the registry data from uro-oncology practices in Germany, retrospectively analyzed the information contained in the IQUO (Association for uro-oncological quality assurance) patient registry. They evaluated data prospectively collected from [...]

Efficacy of Long-Term Treatment of > 5-10 Years with the LHRH Drug Leuprorelin (Lupron)

Popular culture tells us that primary androgen deprivation therapy with leuprorelin acetate (Lupron) will not work for longer than two years!  This is a significant and very problematic statement given that all of us with metastatic prostate cancer rely on delaying the move to any other treatments, especially given their cost to the quality of our life. In an observational, retrospective study evaluating this statement as well as the efficacy and safety of the use of Lupron, 30 office-based urologists in Germany evaluated 647 men from 1992 to 2012. The study broke up the 647 men into three subgroups which [...]

Predicting Survival in Men with Spinal Cord Compression from Metastatic Prostate Cancer

There was a recent study to investigate the predictive value of the number of extra-spinal organs involved by metastases for survival in metastatic spinal cord compression (MSCC) from prostate cancer. This was a very small study of only 95 men irradiated with 10×3 Gy for MSCC from prostate cancer. The investigators considered seven factors: Age, performance score, number of involved vertebrae, interval from prostate cancer diagnosis to MSCC, pre-radiotherapy ambulatory status, time to motor deficits development, number of involved extra-spinal organs. They found that the six-month survival rates for 0, 1 and ?2 involved extra-spinal organs, were 81, 53 and [...]